Vertex Pharmaceuticals (NasdaqGS:VRTX) Advances Diabetes Portfolio Despite 2% Decline in Share Price
Vertex Pharmaceuticals (NasdaqGS:VRTX) saw a notable 20.53% share price increase over the last quarter, which coincided with several key developments in its Type 1 Diabetes (T1D) initiatives. The ...
Managed Healthcare Executive3d
Nonopioid Pain Drug Journavx Gaining Traction With High Potential
According to a Vertex spokesperson, the drug is seeing strong initial market adoption, with growing payer coverage and ...
Investing6d
Vertex Pharmaceuticals’ SWOT analysis: stock poised for growth amid challenges
Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biopharmaceutical ... The company’s recent approval of Alyftrek for CF and the anticipated launch of Journavx for acute pain management mark important ...
Managed Healthcare Executive6d
Is Journavx a Step Forward In Pain Management or a Repeat of Past Mistakes?
Doerring, M.D., former FDA medical officer in the division of psychiatry and the founder and CEO of TaperClinic, he shares ...
Rattled by the Stock Market Sell-Off? These 3 Stocks Outperformed the S&P 500 During the Great Recession
The economy has been on shaky ground for a while, and President Trump's tariffs and trade wars could finally send it into a ...
Yahoo Finance4d
Vertex Pharmaceuticals Incorporated (VRTX)
Vertex Pharmaceuticals (VRTX ... retain it for some time to see if its CF sales continue to rise and how the Journavx and Alyftrek launch progress. Fear, uncertainty, and doubt have become ...
Investing Snacks5d
Painfully Profitable: Vertex’s Shot Beyond CF
Vertex Pharmaceuticals is flexing its innovation muscles beyond its cystic fibrosis stronghold, charging into new territories ...
Investing Snacks6d
Vertex Flexes Muscles Beyond Cystic Fibrosis
Vertex Pharmaceuticals is marching beyond its cystic fibrosis stronghold with bold steps into pain management and genetic ...